- All
- Featured news
- News
28Nov2013
Professor Dr. Helma Wennemers nominated for election to Board of Directors
Professor Dr. Helma Wennemers nominared for election to Board of Directors and early cancellation of...
08Oct2013
Bachem and GlyTech Nominated for Innovation Award at CPHI Worldwide Forum
Bachem and GlyTech have been shortlisted in the CPhI Pharma Awards for Innovation in Process Develop...
23Aug2013
Half-Year Report 2013: Confirmation of upward trend
Bachem Group (SIX: BANB) continued to grow in the first half of 2013. Sales increased 7.3% from the ...
15Mar2013
2012 financial year: Bachem clearly tops prior-year results at all levels
Bachem Group generated sales of 157.3 million CHF in the 2012 financial year...
11Mar2011
Bachem regains the upswing – significantly improved Business Performance in second semester
The Bachem Group gained significant momentum in the second half of 2010 after a slow start to the ye...
09Sep2010
Bachem and Atheris collaborate on Melusine® venom peptide libraries for lead discovery
Bachem today announced that the company concluded an agreement with Atheris Laboratories to market t...
Careers
At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.
View all jobs
Click here >>
Contact
We look forward to partnering with you to build up your project development plan for CMC development according to your unique needs.
No matter what stage your NCE is in – pre-IND, early or late clinical stages, or already on the market – contact us to find out what we can do for you.